Imaging of lung cancer in the era of molecular medicine.

[1]  M. Baumann,et al.  Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy. , 2010, Lung cancer.

[2]  A. Padhani,et al.  Multiparametric imaging of tumor response to therapy. , 2010, Radiology.

[3]  C. V. van Kuijk,et al.  Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? , 2010, European Radiology.

[4]  V. Goh,et al.  Quantitative helical dynamic contrast enhanced computed tomography assessment of the spatial variation in whole tumour blood volume with radiotherapy in lung cancer. , 2010, Lung cancer.

[5]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[7]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[8]  A. Gazdar.  Personalized medicine and inhibition of EGFR signaling in lung cancer. , 2009, The New England journal of medicine.

[9]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[10]  Harry J de Koning,et al.  Management of lung nodules detected by volume CT scanning. , 2009, The New England journal of medicine.

[11]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[12]  Ultan McDermott,et al.  Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Regev,et al.  SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas , 2009, Nature Genetics.

[14]  M. Ladanyi,et al.  Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. , 2009, Archives of pathology & laboratory medicine.

[15]  Gregory J Riely,et al.  Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials , 2009, Clinical Cancer Research.

[16]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[17]  Binsheng Zhao,et al.  Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. , 2009, Radiology.

[18]  Jeffrey Settleman,et al.  Case 23-2008 , 2009 .

[19]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[20]  W. Pao,et al.  KRAS mutations in non-small cell lung cancer. , 2009, Proceedings of the American Thoracic Society.

[21]  Kyle J Myers,et al.  Noncalcified lung nodules: volumetric assessment with thoracic CT. , 2009, Radiology.

[22]  Lawrence H. Schwartz,et al.  Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers* , 2009, Journal of Nuclear Medicine.

[23]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[24]  Peter J. Ell,et al.  Metabolic–flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  K. Okudela,et al.  Molecular and Genetic Pathogenesis of Lung Cancer: Differences Between Small-Cell and Non-Small-Cell Carcinomas , 2008 .

[26]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[27]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[28]  L. Sequist,et al.  Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung. , 2008, The New England journal of medicine.

[29]  Minming Zhang,et al.  Quantitative investigation of solitary pulmonary nodules: dynamic contrast-enhanced MRI and histopathologic analysis. , 2008, AJR. American journal of roentgenology.

[30]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Gladish,et al.  Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  Hirofumi Fujii,et al.  Radiologic measurements of tumor response to treatment: practical approaches and limitations. , 2008, Radiographics : a review publication of the Radiological Society of North America, Inc.

[33]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[34]  M. Tunaci,et al.  Dynamic contrast enhancement patterns of solitary pulmonary nodules on 3D gradient-recalled echo MRI. , 2007, AJR. American journal of roentgenology.

[35]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[36]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[37]  William Pao,et al.  Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus , 2007, Clinical Cancer Research.

[38]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[39]  David W Townsend,et al.  Time Course of Early Response to Chemotherapy in Non–Small Cell Lung Cancer Patients with 18F-FDG PET/CT , 2007, Journal of Nuclear Medicine.

[40]  J. Minna,et al.  A Translational View of the Molecular Pathogenesis of Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  T. Goya,et al.  Abnormalities of epidermal growth factor receptor in lung squamous‐cell carcinomas, adenosquamous carcinomas, and large‐cell carcinomas , 2007, Cancer.

[42]  P. Nederlof,et al.  EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  Wolfgang A Weber,et al.  Monitoring cancer treatment with PET/CT: does it make a difference? , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  L. Schwartz,et al.  Lung cancer: computerized quantification of tumor response--initial results. , 2006, Radiology.

[45]  M. Nishimura,et al.  A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations , 2006, British Journal of Cancer.

[46]  M. Maemondo,et al.  Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Meyerson,et al.  Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[48]  F. Hirsch,et al.  Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Y. Bang,et al.  Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation , 2006, Clinical Cancer Research.

[50]  R Tibshirani,et al.  Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification , 2006, Oncogene.

[51]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[52]  M. Chung,et al.  Solitary Pulmonary Nodule : Characterization with Combined Wash-in and Washout Features at Dynamic Multi – Detector Row CT 1 , 2005 .

[53]  Gayatry Mohapatra,et al.  Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR , 2005, Nature Genetics.

[54]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[55]  F. Hirsch,et al.  Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[58]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[59]  S. Matsumoto,et al.  Prognostic value of dynamic MR imaging for non‐small‐cell lung cancer patients after chemoradiotherapy , 2005, Journal of magnetic resonance imaging : JMRI.

[60]  P. Jänne,et al.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Daniel C Sullivan,et al.  Functional imaging in lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[63]  Binsheng Zhao,et al.  Pulmonary metastases: effect of CT section thickness on measurement--initial experience. , 2005, Radiology.

[64]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[65]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[66]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[67]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Thie.  Understanding the standardized uptake value, its methods, and implications for usage. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[69]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  F. Schick,et al.  Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging--perfusion differences in malignant and benign lesions. , 2004, Radiology.

[71]  A. D. Van den Abbeele,et al.  Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[73]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[74]  Simina C. Fluture,et al.  Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT. , 2004, Radiology.

[75]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[76]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  N. Müller,et al.  Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: correlation with tumor vascularity and prognosis. , 2003, Radiology.

[78]  M. Knopp,et al.  Functional tumor imaging with dynamic contrast‐enhanced magnetic resonance imaging , 2003, Journal of magnetic resonance imaging : JMRI.

[79]  Hiroto Hatabu,et al.  Solitary pulmonary nodules: potential role of dynamic MR imaging in management initial experience. , 2002, Radiology.

[80]  Torsten Mattfeldt,et al.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. , 2002, Cancer research.

[81]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[82]  A. Hölscher,et al.  Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  B. Freidlin,et al.  Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Binsheng Zhao,et al.  Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. , 2000, Radiology.

[85]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[86]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[87]  R R Edelman,et al.  Quantitative assessment of pulmonary perfusion with dynamic contrast‐enhanced MRI , 1999, Magnetic resonance in medicine.

[88]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[89]  D Delbeke,et al.  Prospective investigation of positron emission tomography in lung nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  R R Edelman,et al.  Pulmonary perfusion: Qualitative assessment with dynamic contrast‐enhanced MRI using ultra‐short TE and inversion recovery turbo FLASH , 1996, Magnetic resonance in medicine.

[92]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[93]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[94]  S. Rodenhuis,et al.  Clinical significance of ras oncogene activation in human lung cancer. , 1992, Cancer research.

[95]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[96]  R. Scully,et al.  Case records of the Massachusetts General Hospital. , 1990 .

[97]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[98]  H. Lodish,et al.  Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. , 1987, Science.

[99]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[100]  H. Stünzi,et al.  Tumours of the lung. , 1974, Bulletin of the World Health Organization.

[101]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[102]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.